ISC organises the 8th edition of the UNGA77 Science Summit around the 77th United Nations General Assembly.
Session: Achieving health for all and meeting the Sustainable Development Goals through inclusive research and development and equitable access: Best practices and lessons learned
Co-organized by DNDi, Medicines for Malaria Venture, and TB Alliance
Nearly three years after the start of the COVID-19 pandemic, the critical importance of investing in biomedical research and development (R&D) to achieve Health for All has become more apparent than ever. New, effective vaccines were developed with unprecedented speed thanks to a level of global investment and collaboration in R&D that matched the urgency of the crisis. However, these remarkable efforts also exposed serious gaps in equitable access to health tools, technologies, and services, which have had a negative impact on key areas of development. The lesson is clear: investing in both biomedical innovation and equitable access is necessary to achieve Health for All, which in turn is a driver for sustainable development. Join us for an interactive discussion on how good practices in innovation are contributing to the achievement of the third Sustainable Development Goal, and the solutions needed at the global, regional, and national levels to support sustainable and expanded scientific collaborations.
Date: Thursday, 29 September 2022
Time: 8:00-9:30 AM
Moderator: Boghuma Kabisen Titanji, Assistant Professor of Medicine, Emory University
Speakers:
- Anna Doubell, COO, Policy Cures Research
- Marcus Vinícius Guimarães de Lacerda, Infectious Disease Physician and Public Health Specialist, Tropical Medicine Foundation Dr. Heitor Vieira Dourado (FMT- HVD) and Leônidas and Maria Deane Institute (ILMD/Fiocruz Amazonia)
- Osamu Kunii, CEO, Global Health Innovative Technology Fund (GHIT Fund)
- Andrea Lucard, Executive Vice-President, Medicines for Malaria Venture
- Maurine Murenga, Executive Director, Lean On Me Foundation
- Norbert Ndjeka, Chief Director of TB Control and Management, National Department of Health, South Africa
- Luis Pizarro, Executive Director, DNDi
- Radha Rangarajan, Director, Central Drug Research Institute, Council of Scientific and Industrial Research, Uttar Pradesh, India
- Mel Spigelman, President and Chief Executive Officer, TB Alliance
- Soumya Swaminathan, Chief Scientist, World Health Organization (WHO)
